The DOI matches its Crossref record; 420 of the 420 references it cites were found in a registry or an index.
Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
Open accessAbstract
Defects in alternative splicing are frequently found in human tumors and result either from mutations in splicing‐regulatory elements of specific cancer genes or from changes in the regulatory splicing machinery. RNA splicing regulators have emerged as a new class of oncoproteins and tumor suppressors, and contribute to disease progression by modulating RNA isoforms involved in the hallmark cancer pathways. Thus, dysregulation of alternative RNA splicing is fundamental to cancer and provides a potentially rich source of novel therapeutic targets. Here, we review the alterations in splicing regulatory factors detected in human tumors, as well as the resulting alternatively spliced isoforms that impact cancer hallmarks, and discuss how they contribute to disease pathogenesis. RNA splicing is a highly regulated process and, as such, the regulators are themselves tightly regulated. Differential transcriptional and posttranscriptional regulation of splicing factors modulates their levels and activities in tumor cells. Furthermore, the composition of the tumor microenvironment can also influence which isoforms are expressed in a given cell type and impact drug responses. Finally, we summarize current efforts in targeting alternative splicing, including global splicing inhibition using small molecules blocking the spliceosome or splicing‐factor‐modifying enzymes, as well as splice‐switching RNA‐based therapeutics to modulate cancer‐specific splicing isoforms. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Processing > Splicing Regulation/Alternative Splicing
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 420
Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.
Midis, G. P., Shen, Y., & Owen‐Schaub, L. B. (1996) · PubMed · Cited by 137
Watermann, D. O., Tang, Y., Hausen, A. Z., Jäger, M., Stamm, S., & Stickeler, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-3294 · Cited by 136
Adib‐Conquy, M., Adrie, C., Fitting, C., Gattolliat, O., Beyaert, R., & Cavaillon, J. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000233875.93866.88 · Cited by 135
Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma
Pritchard‐Jones, R., Dunn, D., Qiu, Y., Varey, A. H. R., Orlando, A., Rigby, H., Harper, S. J., & Bates, D. O. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603839 · Cited by 133
Matos, P., Collard, J. G., & Jordan, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308215200 · Cited by 133
S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A. R., Davidson, B., & Karni, R. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.11.020 · Cited by 133
Lu, Y., Yao, H., & Wang, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.007 · Cited by 132
The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice
Rennel, E. S., Waine, E., Guan, H., Schüler, Y., Leenders, W. P. J., Woolard, J., Sugiono, M., Gillatt, D. A., Kleinerman, E. S., Bates, D. O., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604309 · Cited by 131
Pilch, B., Allemand, E., Facompré, M., et al. (2001) · PubMed · Cited by 130
Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons
Wang, Z., Chatterjee, D., Jeon, H. Y., Akerman, M., Heiden, M. G. V., Cantley, L. C., & Krainer, A. R. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr030 · Cited by 126
Osteopontin splice variants and polymorphisms in cancer progression and prognosis
Briones-Orta, M. A., Avendaño-Vázquez, S. E., Aparicio‐Bautista, D. I., Coombes, J. D., Weber, G. F., & Syn, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.005 · Cited by 126
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
Burd, C. J., Petre, C. E., Morey, L. M., Wang, Y., Revelo, M. P., Haiman, C. A., Lu, S., Fenoglio‐Preiser, C. M., Li, J., Knudsen, E. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506281103 · Cited by 125
Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function
Mandal, M., Vadlamudi, R. K., Nguyen, D. N., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008514200 · Cited by 123
Tumor suppressor properties of the splicing regulatory factor RBM10
Hernández, J., Bechara, E., Schlesinger, D., Delgado, J., Serrano, L. G., & Valcárcel, J. (2016) · RNA Biology · doi:10.1080/15476286.2016.1144004 · Cited by 122
Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation
Maimon, A., Mogilevsky, M., Shilo, A., Golan‐Gerstl, R., Obiedat, A., Ben-Hur, V., Lebenthal-Loinger, I., Stein, I., Reich, R., Beenstock, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.041 · Cited by 121
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer
Yoshida, T., Kim, J. H., Carver, K. C., Su, Y., Weremowicz, S., Mulvey, L. A., Yamamoto, S., Brennan, C., Mei, S., Long, H. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2443 · Cited by 120
KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival
Hatami, R., Sieuwerts, A. M., Izadmehr, S., Yao, Z., Qiao, R., Papa, L., Look, M. P., Smid, M., Ohlseen, J., Levine, A. C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004688 · Cited by 120
Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
Lapuk, A. V., Marr, H., Jakkula, L. R., Pedro, H., Bhattacharya, S., Purdom, E. A., Hu, Z., Simpson, K., Pachter, L. S., Durinck, S., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0528 · Cited by 119
He, X., Pool, M. D., Darcy, K. M., Lim, S. B., Auersperg, N., Coon, J. S., & Beck, W. T. (2007) · Oncogene · doi:10.1038/sj.onc.1210307 · Cited by 117
Goel, H. L., Gritsko, T. M., Pursell, B. M., Chang, C., Shultz, L. D., Greiner, D. L., Norum, J. H., Toftgård, R., Shaw, L. M., & Mercurio, A. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.059 · Cited by 116
Ibrahimpašić, T., Xu, B., Landa, I., Doğan, S., Middha, S., Seshan, V., Deraje, S., Carlson, D. L., Migliacci, J. C., Knauf, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1183 · Cited by 116
Oltean, S., Sorg, B. S., Albrecht, T. R., Bonano, V. I., Brazas, R. M., Dewhirst, M. W., & García-Blanco, M. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603090103 · Cited by 114
Modugno, F. D., Iapicca, P., Boudreau, A., Mottolese, M., Terrenato, I., Perracchio, L., Carstens, R. P., Santoni, A., Bissell, M. J., & Nisticò, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214394109 · Cited by 114
Scheper, G. C., Parra-Palau, J. L., Wilson, M., van Kollenburg, B., Vertegaal, A. C. O., Han, Z., & Proud, C. G. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5692-5705.2003 · Cited by 113
Gonçalves, V., Henriques, A. F. A., Pereira, J., Neves‐Costa, A., Moyer, M. P., Moita, L. F., Gama‐Carvalho, M., Matos, P., & Jordan, P. (2014) · RNA · doi:10.1261/rna.041376.113 · Cited by 112
Goswami, S. K., Philippar, U., Sun, D., Patsialou, A., Avraham, J. T., Wang, W., Modugno, F. D., Nisticò, P., Gertler, F. B., & Condeelis, J. S. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9225-8 · Cited by 112
SF3B1 Association with Chromatin Determines Splicing Outcomes
Kfir, N., Lev-Maor, G., Glaich, O., Alajem, A., Datta, A., Sze, S. K., Meshorer, E., & Ast, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.048 · Cited by 111
Alternative splicing networks regulated by signaling in human T cells
Martínez, N. M., Pan, Q., Cole, B. S., Yarosh, C. A., Babcock, G. A., Heyd, F., Zhu, W., Ajith, S., Blencowe, B. J., & Lynch, K. W. (2012) · RNA · doi:10.1261/rna.032243.112 · Cited by 109
The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis
Zhou, C., Licciulli, S., Avila, J. L., Cho, M., Troutman, S. A., Jiang, P., Kossenkov, A. V., Showe, L. C., Liu, Q., Vachani, A., et al. (2012) · Oncogene · doi:10.1038/onc.2012.99 · Cited by 108
Liu, W.-R., Tian, M., Yang, L., Lin, Y., Jin, L., Ding, Z., Shen, Y., Peng, Y., Gao, D., Zhou, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2749 · Cited by 107
Meseguer, S., Mudduluru, G., Escamilla, J. M., Allgayer, H., & Barettino, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.167817 · Cited by 107
Expression of splicing factors in human ovarian cancer
Fischer, D., Noack, K., Runnebaum, I. B., Watermann, D. O., Kieback, D., Stamm, S., & Stickeler, E. (2004) · Oncology Reports · doi:10.3892/or.11.5.1085 · Cited by 106
Yea, S., Narla, G., Zhao, X. Y., Garg, R., Kremer-Tal, S., Hod, E. A., Villanueva, A., Loke, J. C., Tarocchi, M., Akita, K., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.015 · Cited by 106
He, X., Arslan, A. D., Ho, T.-T., Yuan, C., Stampfer, M. R., & Beck, W. T. (2014) · Oncogenesis · doi:10.1038/oncsis.2013.47 · Cited by 105
Expression of the H-ras proto-oncogene is controlled by alternative splicing
Cohen, J. B., Broz, S. D., & Levinson, A. D. (1989) · Cell · doi:10.1016/0092-8674(89)90427-3 · Cited by 105
Fukuda, T., Yoshida, N., Kataoka, Y., Manabe, R., Mizuno-Horikawa, Y., Sato, M., Kuriyama, K., Yasui, N., & Sekiguchi, K. (2002) · PubMed · Cited by 104
Komeno, Y., Huang, Y.-J., Qiu, J., Lin, L., Xu, Y., Zhou, Y., Chen, L., Monterroza, D. D., Li, H., DeKelver, R. C., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00202-15 · Cited by 104
Jiang, C. C., Lai, F., Tay, K. H., Croft, A. J., Rizos, H., Becker, T. M., Yang, F., Liu, H., Thorne, R. F., Hersey, P., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.48 · Cited by 104
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing
Rigo, F., Hua, Y., Chun, S. J., Prakash, T. P., Krainer, A. R., & Bennett, C. F. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.939 · Cited by 104
He, X., Ee, P. L. R., Coon, J. S., & Beck, W. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0439 · Cited by 103
Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia
Liu, J. H., Wei, S., Lamy, T., Li, Y., Epling‐Burnette, P. K., Djeu, J. Y., & Loughran, T. P. (2002) · Blood · doi:10.1182/blood.v100.4.1449.h81602001449_1449_1453 · Cited by 102
The alternative splicing side of cancer
Biamonti, G., Catillo, M., Pignataro, D. S., Montecucco, A., & Ghigna, C. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.03.016 · Cited by 101
Shen, H., Zheng, X., Luecke, S., & Green, M. R. (2010) · Genes & Development · doi:10.1101/gad.1974810 · Cited by 101
Zhou, J. M., Allred, D. C., Avis, I. M., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010631915831 · Cited by 99
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
Yip, B. H., Steeples, V., Repapi, E., Armstrong, R. N., Llorian, M., Roy, S., Shaw, J. M., Dolatshad, H., Taylor, S., Verma, A. K., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91363 · Cited by 99
Bordeleau, F., Califano, J. P., Abril, Y. L. N., Mason, B. N., LaValley, D. J., Shin, S. J., Weiss, R. S., & Reinhart‐King, C. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505421112 · Cited by 97
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan‐Halevy, I., Rosenblum, D., Goldsmith, M., Avigdor, A., Benjamini, O., Bairey, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519273113 · Cited by 97
Tejedor, J. R., Papasaikas, P., & Valcárcel, J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.029 · Cited by 95
Predominant expression of the long isoform of Bcl‐x (Bcl‐xL) in human lymphomas
Xerri, L., Parc, P., Brousset, P., Schlaifer, D., Hassoun, J., Reed, J. C., Krajewski, S., & Birnbaum, D. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.423958.x · Cited by 94
Mohammad, G. H., Damink, S. W. M. O., Malagó, M., Dhar, D. K., & Pereira, S. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151635 · Cited by 94
Kon, A., Yamazaki, S., Nannya, Y., Kataoka, K., Ota, Y., Nakagawa, M. M., Yoshida, K., Shiozawa, Y., Morita, M., Yoshizato, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-762393 · Cited by 93
Izaguirre, D. I., Zhu, W., Hai, T., Beird, H. C., Krahe, R., & Cote, G. J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20859 · Cited by 92
Isoforms of Receptors of Fibroblast Growth Factors
Gong, S. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24649 · Cited by 91
RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer
Sutherland, L. C., Wang, K., & Robinson, A. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c6e330 · Cited by 91
The impact of SF3B1 mutations in CLL on the DNA-damage response
Raa, G. D. T., Derks, I. A. M., Navrkalová, V., Skowrońska, A., Moerland, P. D., van Laar, J., Oldreive, C., Monsuur, H. N., Trbušek, M., Malčíková, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.318 · Cited by 91
Topp, J. D., Jackson, J., Melton, A. A., & Lynch, K. W. (2008) · RNA · doi:10.1261/rna.1212008 · Cited by 90
Bielli, P., Bordi, M., Biasio, V. D., & Sette, C. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku922 · Cited by 90
Zhao, J., Sun, Y., Huang, Y., Song, F., Huang, Z., Bao, Y., Zuo, J., Saffen, D. W., Shao, Z., Liu, W., et al. (2017) · Scientific Reports · doi:10.1038/srep40488 · Cited by 90
Jin, W., McCutcheon, I. E., Fuller, G. N., et al. (2000) · PubMed · Cited by 89
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
Castagnoli, L., Iezzi, M., Ghedini, G. C., Ciravolo, V., Marzano, G., Lamolinara, A., Zappasodi, R., Gasparini, P., Campiglio, M., Amici, A. R. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0983 · Cited by 89
Millar, E. K. A., Dean, J. L., McNeil, C. M., O’Toole, S. A., Henshall, S. M., Tran, T. H., Lin, J., Quong, A. A., Comstock, C. E. S., Witkiewicz, A. K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.13 · Cited by 88
Modugno, F. D., Monte, L. B. D., Balsamo, M., Bronzi, G., Nicotra, M. R., Alessio, M., Jäger, E., Condeelis, J. S., Santoni, A., Natali, P. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1997 · Cited by 87
SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells
Gautrey, H., Jackson, C. R., Dittrich, A.-L., Browell, D., Lennard, T. W. J., & Tyson-Capper, A. J. (2015) · RNA Biology · doi:10.1080/15476286.2015.1076610 · Cited by 85
Inoue, A., Sawata, S. Y., Taira, K., & Wadhwa, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607595104 · Cited by 85
Bruno, I., Jin, W., & Cote, G. J. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh272 · Cited by 84
Regulation of Mcl-1 by SRSF1 and SRSF5 in Cancer Cells
Gautrey, H., & Tyson-Capper, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051497 · Cited by 84
Differential splicing across immune system lineages
Ergün, A., Doran, G., Costello, J. C., Paik, H. H.-I., Collins, J. J., Mathis, D. J., Benoist, C. O., Blair, D. A., Dustin, M. L., Shinton, S. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311839110 · Cited by 83
Kashyap, M. K., Kumar, D., Villa, R., Clair, J. J. L., Benner, C. W., Sasik, R., Jones, H., Ghia, E. M., Rassenti, L. Z., Kipps, T. J., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.122069 · Cited by 83
SnapShot: Spliceosome Dynamics III
Wahl, M. C., & Lührmann, R. (2015) · Cell · doi:10.1016/j.cell.2015.07.033 · Cited by 83
Patel, N. A., Chalfant, C. E., Watson, J. E., Wyatt, J. R., Dean, N. M., Eichler, D. C., & Cooper, D. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101260200 · Cited by 83
Ranieri, D., Rosato, B., Nanni, M., Magenta, A., Belleudi, F., & Torrisi, M. R. (2015) · Oncotarget · doi:10.18632/oncotarget.6706 · Cited by 83
Expression of CD44 isoforms in renal cell tumors : positive correlation to tumor differentiation
Terpe, H.-J., Störkel, S., Zimmer, U., Anquez, V., Fischer, C. G., Pantel, K., & Günthert, U. (1996) · Europe PMC (PubMed Central) · doi:10.5451/unibas-ep6605 · Cited by 82
Zhao, Q., Caballero, O. L., Davis, I. D., Jonasch, E., Tamboli, P., Yung, W. K. A., Weinstein, J. N., Strausberg, R. L., & Yao, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3708 · Cited by 82
McGlincy, N. J., Tan, L.-Y., Paul, N., Zavolan, M., Lilley, K. S., & Smith, C. W. J. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-565 · Cited by 82
Paolella, B. R., Gibson, W. J., Urbanski, L. M., Alberta, J. A., Zack, T. I., Bandopadhayay, P., Nichols, C. A., Agarwalla, P. K., Brown, M. S., Lamothe, R. C., et al. (2017) · eLife · doi:10.7554/elife.23268 · Cited by 81
Self-citationSnapShot: Spliceosome Dynamics I
Wahl, M. C., & Lührmann, R. (2015) · Cell · doi:10.1016/j.cell.2015.05.050 · Cited by 81
Anczuków, O., Buisson, M., Léoné, M., Coutanson, C., Lasset, C., Calender, A., Sinilnikova, O. M., & Mazoyer, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1100 · Cited by 80
Self-citationRecombinant human VEGF165b protein is an effective anti-cancer agent in mice
Rennel, E., Hamdollah‐Zadeh, M., Wheatley, E. R., Magnussen, A., Schüler, Y., Kelly, S., Finucane, C. M., Ellison, D. H., Suarez, S., Ballmer‐Hofer, K., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.027 · Cited by 80
Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
Sonvilla, G., Allerstorfer, S., Heinzle, C. F., Stättner, S., Karner, J., Klimpfinger, M., Wrba, F., Fischer, H., Gauglhofer, C., Spiegl‐Kreinecker, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605596 · Cited by 79
Liu, X., Zhou, Y., Lou, Y., & Zhong, H. (2015) · Gene · doi:10.1016/j.gene.2015.11.009 · Cited by 79
Targeting splicing abnormalities in cancer
Agrawal, A. A., Yu, L., Smith, P. G., & Buonamici, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.010 · Cited by 79
Bhattacharya, R., Mitra, T., Chaudhuri, S. R., & Roy, S. S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26504 · Cited by 78
A large‐scale analysis of alternative splicing reveals a key role of QKI in lung cancer
de Miguel, F. J., Pajares, M. J., Martínez‐Terroba, E., Ajona, D., Morales, X., Sharma, R. D., Pardo, F. J., Rouzaut, A., Rubio, Á., Montuenga, L. M., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.08.001 · Cited by 77
Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Takahashi, H., Nishimura, J., Kagawa, Y., Kano, Y., Takahashi, Y., Wu, X., Hiraki, M., Hamabe, A., Konno, M., Haraguchi, N., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0142 · Cited by 76
An extended U2AF65–RNA-binding domain recognizes the 3′ splice site signal
Agrawal, A. A., Salsi, E., Chatrikhi, R., Henderson, S., Jenkins, J. L., Green, M. R., Ermolenko, D. N., & Kielkopf, C. L. (2016) · Nature Communications · doi:10.1038/ncomms10950 · Cited by 75
The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma
Melzer, C., Hass, R., von der Ohe, J., Lehnert, H., & Ungefroren, H. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0175-0 · Cited by 75
Passacantilli, I., Frisone, P., Paola, E. D., Fidaleo, M., & Paronetto, M. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx831 · Cited by 74
Sudemycin E influences alternative splicing and changes chromatin modifications
Convertini, P., Shen, M., Potter, P. M., Palacios, G. F., Lagisetti, C., de la Grange, P., Horbinski, C., Fondufe‐Mittendorf, Y. N., Webb, T. R., & Stamm, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku151 · Cited by 72
The β-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression
Gonçalves, V., Matos, P., & Jordan, P. (2008) · RNA · doi:10.1261/rna.1253408 · Cited by 71
Ghigna, C., de Toledo, M., Bonomi, S., Valacca, C., Gallo, S., Apicella, M., Eperon, I. C., Tazi, J., & Biamonti, G. (2010) · RNA Biology · doi:10.4161/rna.7.4.12744 · Cited by 70
Wang, Y., Dean, J. L., Millar, E. K. A., Tran, T. H., McNeil, C. M., Burd, C. J., Henshall, S. M., Utama, F. E., Witkiewicz, A. K., Rui, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3170 · Cited by 70
A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response
DiFeo, A. V., Feld, L. D., Rodríguez, E., Wang, C., Beer, D. G., Martignetti, J. A., & Narla, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2604 · Cited by 70
Comparative Genomics RNAi Screen Identifies Eftud2 as a Novel Regulator of Innate Immunity
Arras, L. D., Laws, R. L., Leach, S. M., Pontis, K., Freedman, J. H., Schwartz, D. A., & Alper, S. (2013) · Genetics · doi:10.1534/genetics.113.160499 · Cited by 70
Xargay‐Torrent, S., López‐Guerra, M., Rosich, L., Montraveta, A., Roldán, J., Rodríguez, V., Villamor, N., Aymerich, M., Lagisetti, C., Webb, T. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4212 · Cited by 69
Xu, X.-M., Wang, D., Shen, Q., Chen, Y., & Wang, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207907 · Cited by 69
Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes
Shkreta, L., Froehlich, U., Paquet, É. R., Toutant, J., Elela, S. A., & Chabot, B. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0192 · Cited by 69
Increased Rac1b Expression Sustains Colorectal Tumor Cell Survival
Matos, P., & Jordan, P. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0008 · Cited by 68
Regulation of androgen receptor splice variant AR3 by PCGEM1
Zhang, Z., Zhou, N., Huang, J., Ho, T.-T., Zhu, Z., Qiu, Z., Zhou, X., Bai, C., Wu, F., Xu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7139 · Cited by 68
Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells
Solier, S., Lansiaux, A., Logette, E., Wu, J. Y., Soret, J., Tazi, J., Bailly, C., Desoche, L., Solary, É., & Corcos, L. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.53.2.1 · Cited by 67
Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
Alajati, A., Sausgruber, N., Aceto, N., Duss, S., Sarret, S., Voshol, H., Bonenfant, D., & Bentires‐Alj, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3186 · Cited by 67
Expression of RBM5‐related factors in primary breast tissue
Rintala‐Maki, N. D., Goard, C. A., Langdon, C. E., Wall, V. E., Traulsen, K. E. A., Morin, C. D., Bonin, M., & Sutherland, L. C. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21134 · Cited by 67
Ishiwata, T., Matsuda, Y., Yamamoto, T., Uchida, E., Korc, M., & Naito, Z. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.020 · Cited by 67
Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., & Jodrell, D. I. (2003) · PubMed · Cited by 67
Regulation of Toll-like Receptor Signaling by the SF3a mRNA Splicing Complex
O’Connor, B. P., Danhorn, T., Arras, L. D., Flatley, B. R., Marcus, R. A., Farias‐Hesson, E., Leach, S. M., & Alper, S. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1004932 · Cited by 66
Tong, A., Nguyen, J., & Lynch, K. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508123200 · Cited by 66
Zhou, R., Shañas, R., Nelson, M. A., Bhattacharyya, A. K., & Shi, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24744 · Cited by 65
Anantha, R. W., Alcivar, A. L., Ma, J., Cai, H., Simhadri, S. R., Ule, J., König, J., & Xia, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061368 · Cited by 65
Pelisch, F., Khauv, D., Risso, G., Stallings‐Mann, M. L., Blaustein, M., Quadrana, L., Radisky, D. C., & Srebrow, A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24103 · Cited by 65
Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides
Wang, Z., Jeon, H. Y., Rigo, F., Bennett, C. F., & Krainer, A. R. (2012) · Open Biology · doi:10.1098/rsob.120133 · Cited by 65
Sharma, S., Wongpalee, S. P., Vashisht, A. A., Wohlschlegel, J. A., & Black, D. L. (2014) · Genes & Development · doi:10.1101/gad.248625.114 · Cited by 63
Mende, Y., Jakubik, M., Rießland, M., Schoenen, F. J., Roßbach, K., Kleinridders, A., Köhler, C. N., Buch, T., & Wirth, B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq094 · Cited by 63
Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis
Zhu, H., Luo, H., Zhu, X., Hu, X., Zheng, L., & Zhu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13703 · Cited by 63
Verduci, L., Simili, M., Rizzo, M., Mercatanti, A., Evangelista, M., Mariani, L., Rainaldi, G., & Pitto, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.114736 · Cited by 61
Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary Oncogenesis
Cha, J. Y., Lambert, Q. T., Reuther, G. W., & Der, C. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0187 · Cited by 61
Sweetser, D. A., Peniket, A. J., Haaland, C. M., Blomberg, A. A., Zhang, Y., Zaidi, S. T., Dayyani, F., Zheng, Z. S., Heerema, N. A., Boultwood, J., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20236 · Cited by 60
Rare SF3B1 R625 mutations in cutaneous melanoma
Kong, Y., Krauthammer, M. O., & Halaban, R. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000071 · Cited by 60
Solier, S., Barb, J. J., Zeebèrg, B. R., Varma, S., Ryan, M. C., Kohn, K. W., Weinstein, J. N., Munson, P. J., & Pommier, Y. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2491 · Cited by 60
HnRNP L and L-like cooperate in multiple-exon regulation of CD45 alternative splicing
Preußner, M., Schreiner, S., Hung, L.-H., Porstner, M., Jäck, H., Beneš, V., Rätsch, G., & Bindereif, A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks221 · Cited by 59
The tumor suppressing effects of QKI-5 in prostate cancer
Zhao, Y. D., Zhang, G., Wei, M., Lu, X., Fu, H.-Y., Feng, F., Wang, S., Wei, L., Wu, N., Lu, Z., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26722 · Cited by 58
He, X., & Zhang, P. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0422-1 · Cited by 58
Corbo, C., Orrù, S., Gemei, M., Noto, R. D., Mirabelli, P., Imperlini, E., Ruoppolo, M., Vecchio, L. D., & Salvatore, F. (2012) · PROTEOMICS · doi:10.1002/pmic.201100370 · Cited by 58
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma
Zhang, S., Wei, J. S., Li, S. Q., Badgett, T. C., Song, Y. K., Agarwal, S., Coarfa, C., Tolman, C., Hurd, L., Liao, H., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.11.045 · Cited by 58
Wang, C., Norton, J. T., Ghosh, S., Kim, J. J., Fushimi, K., Wu, J. Y., Stack, M. S., & Huang, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803682200 · Cited by 57
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer
Chao, T., Huang, T., Liao, Y.-P., Huang, R., Su, P., Shen, H.-Y., Lai, H., & Wang, Y.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182166 · Cited by 57
The transcription factor FBI‐1 inhibits SAM68‐mediated BCL‐X alternative splicing and apoptosis
Bielli, P., Busà, R., Stasi, S. M. D., Muñoz, M. J., Botti, F., Kornblihtt, A. R., & Sette, C. (2014) · EMBO Reports · doi:10.1002/embr.201338241 · Cited by 56
Regulation of FAS Exon Definition and Apoptosis by the Ewing Sarcoma Protein
Paronetto, M. P., Bernardis, I., Volpe, E., Bechara, E., Sebestyén, E., Eyras, E., & Valcárcel, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.077 · Cited by 56
Shieh, J., Liu, K.-T., Huang, S., Chen, Y., & Hsieh, T. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.83 · Cited by 55
Gabriel, M., Delforge, Y., Deward, A., Habraken, Y., Hennuy, B., Piette, J. G., Klinck, R., Chabot, B., Colige, A., & Lambert, C. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1259-0 · Cited by 55
Ezponda, T., Pajares, M. J., Agorreta, J., Echeveste, J. I., López-Picazo, J. M., Torre, W., Pı́o, R., & Montuenga, L. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0076 · Cited by 55
Piekiełko‐Witkowska, A., Wiszomirska, H., Wójcicka, A., Popławski, P., Bogusławska, J., Tański, Z., & Nauman, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013690 · Cited by 54
Huynh, F. C., & Jones, F. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114419 · Cited by 54
CD28 Costimulation Regulates Genome-Wide Effects on Alternative Splicing
Butte, M. J., Lee, S. J., Jesneck, J. L., Keir, M. E., Haining, W. N., & Sharpe, A. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040032 · Cited by 54
Li, Z., Li, Q., HAN, L., Tian, N., Liang, Q., LI, Y., Zhao, X., Du, C., & Tian, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4465 · Cited by 54
Odunsi, K., Mhawech-Fauceglia, P., Andrews, C., Beck, A., Amuwo, O., Lele, S., Black, J. D., & Huang, R.-Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051030 · Cited by 53
Botella, L. M., Sanz-Rodríguez, F., Komi, Y., Fernández-L, A., Varela, E., Garrido-Martin, E. M., Narla, G., Friedman, S. L., & Kojima, S. (2008) · Biochemical Journal · doi:10.1042/bj20081434 · Cited by 52
Peiqi, L., Zhaozhong, G., Yaotian, Y., Jun, J., Jihua, G., & Rong, J. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.14871 · Cited by 51
Vinayanuwattikun, C., Calvez‐Kelm, F. L., Abedi‐Ardekani, B., Zaridze, D. G., Mukeria, A., Voegele, C., Vallée, M., Purnomosari, D., Forey, N., Durand, G., et al. (2016) · Scientific Reports · doi:10.1038/srep31628 · Cited by 51
Bogusławska, J., Sokół, E., Rybicka, B., Czubaty, A., Rodzik, K., & Piekiełko‐Witkowska, A. (2016) · Gene · doi:10.1016/j.gene.2016.09.031 · Cited by 51
Shiroki, T., Yokoyama, M., Tanuma, N., Maejima, R., Tamai, K., Yamaguchi, K., Oikawa, T., Noguchi, T., Miura, K., Fujiya, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13211 · Cited by 51
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
Augello, M. A., Burd, C. J., Birbe, R., McNair, C. M., Ertel, A., Magee, M. S., Frigo, D. E., Wilder-Romans, K., Shilkrut, M., Han, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64750 · Cited by 50
Splicing-Correcting Therapy for SMA
Wan, L., & Dreyfuss, G. (2017) · Cell · doi:10.1016/j.cell.2017.06.028 · Cited by 50
PKM2 is not required for colon cancer initiated by APC loss
Lau, A. N., Israelsen, W. J., Roper, J., Sinnamon, M. J., Georgeon, L., Dayton, T. L., Hillis, A. L., Yilmaz, Ö. H., Vizio, D. D., Hung, K. E., et al. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0172-1 · Cited by 50
Kamihira, S., Yamada, Y., Tomonaga, M., Sugahara, K., & Tsuruda, K. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01792.x · Cited by 49
Splicing inhibition of U2AF65 leads to alternative exon skipping
Cho, S., Moon, H., Loh, T., Jang, H., Liu, Y.-C., Zhou, J.-H., Ohn, T., Zheng, X.-X., & Shen, H.-H. (2015) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1500639112 · Cited by 48
CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis
Sosulski, A., Horn, H., Zhang, L., Coletti, C. M., Vathipadiekal, V., Castro, C. M., Birrer, M. J., Nagano, O., Saya, H., Lage, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156595 · Cited by 48
Dolatshad, H., Pellagatti, A., Fernández‐Mercado, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.178 · Cited by 48
Fagg, W. S., Liu, N., Fair, J. H., Shiue, L., Katzman, S. J., Donohue, J. P., & Ares, M. (2017) · Genes & Development · doi:10.1101/gad.302059.117 · Cited by 48
Palve, V., Mallick, S., Ghaisas, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111927 · Cited by 47
Huang, C., Shen, C., Wang, H.-W., Wu, P., & Cheng, C. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.06.001 · Cited by 46
Rac1, but Not Rac1B, Stimulates RelB-mediated Gene Transcription in Colorectal Cancer Cells
Matos, P., & Jordan, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513243200 · Cited by 46
Kornmann, M., Ishiwata, T., Matsuda, K., Lopez, M. E., Fukahi, K., Asano, G., Beger, H. G., & Korc, M. (2002) · Gastroenterology · doi:10.1053/gast.2002.34174 · Cited by 45
Hartel, M., Narla, G., Wente, M. N., Giese, N. A., Martignoni, M. E., Martignetti, J. A., Friess, H., & Friedman, S. L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.030 · Cited by 45
Jiang, P., Li, Z., Tian, F., Li, X., & Yang, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4018 · Cited by 45
He, Y., Wang, Y., Liu, H., Xu, X., He, S., Tang, J., Huang, Y., Miao, X., Wu, Y., Wang, Q., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.09.019 · Cited by 44
Tazi, J., Bakkour, N., Soret, J., Zekri, L., Hazra, B., Laine, W., Baldeyrou, B., Lansiaux, A., & Bailly, C. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007633 · Cited by 44
Redirecting splicing with bifunctional oligonucleotides
Brosseau, J., Lucier, J., Lamarche, A.-A., Shkreta, L., Gendron, D., Lapointe, E., Thibault, P., Paquet, É. R., Perreault, J., Elela, S. A., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1287 · Cited by 44
Guil, S., de la Iglesia, N., Fernández-Larrea, J., Cifuentes, D., Ferrer, J. C., Guinovart, J. J., & Bach‐Elias, M. (2003) · PubMed · Cited by 44
MiR-30a-5p is induced by Wnt/β-catenin pathway and promotes glioma cell invasion by repressing NCAM
Wang, Z., Dai, X., Chen, Y., Sun, C., Zhu, Q., Zhao, H., Liu, G., Huang, Q., & Lan, Q. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.007 · Cited by 43
Park, S. J., Lee, H., Jo, D. S., Jo, Y. K., Shin, J. H., Kim, H. B., Seo, H. M., Rubinsztein, D. C., Koh, J., Lee, E. K., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.10.017 · Cited by 43
Schiefner, A., Gebauer, M., & Skerra, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303131 · Cited by 43
RNA-binding motif protein 35A is a novel tumor suppressor for colorectal cancer
Leontieva, O. V., & Ionov, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7679 · Cited by 41
Lü, W., Cao, Y., Zhang, Y., Li, S., Gao, J., Wang, X.-A., Mu, J., Hu, Y., Jiang, L., Dong, P., et al. (2016) · Scientific Reports · doi:10.1038/srep26351 · Cited by 41
hnRNP A1 contacts exon 5 to promote exon 6 inclusion of apoptotic Fas gene
Oh, H. K., Lee, E., Jang, H. N., Lee, J., Moon, H., Sheng, Z., Jun, Y., Loh, T. J., Cho, S., Zhou, J., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0824-8 · Cited by 38
Nielsen, T. Ø., Sorensen, S., Dagnæs‐Hansen, F., Kjems, J., & Sørensen, B. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.247 · Cited by 38
Juan, W. C., Roca, X., & Ong, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095210 · Cited by 38
Li, R., An, S., Chen, Z. H., Zhang, G.-C., Zhu, J.-Q., Nie, Q., Xie, Z., Guo, A., Mok, T. S. K., & Wu, Y.-L. L. C. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.05.008 · Cited by 37
Bria, E., Modugno, F. D., Sperduti, I., Iapicca, P., Visca, P., Alessandrini, G., Antoniani, B., Pilotto, S., Ludovini, V., Vannucci, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2609 · Cited by 36
Jin, S., Su, H., Tran, N. T., Song, J., Lu, S. X., Li, Y., Huang, S., Abdel-Wahab, O. I., Liu, Y., & Zhao, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175523 · Cited by 36
Leu, S., Lin, Y.-M., Wu, C.-H., & Ouyang, P. (2012) · Journal of Cell Science · doi:10.1242/jcs.100859 · Cited by 35
Wu, F., Luo, L., Liu, Y., Zhan, Q.-X., Luo, C., Luo, J., Zhang, G., & Feng, Z. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.044 · Cited by 35
Kim, C. J., Nishi, K., Isono, T., Okuyama, Y., Tambe, Y., Okada, Y., & Inoue, H. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20547 · Cited by 35
Krieger, S., Vergnaud, J., Roussel, M., Troussard, X., & Sola, B. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-238 · Cited by 34
Exon 9 skipping of apoptotic caspase-2 pre-mRNA is promoted by SRSF3 through interaction with exon 8
Jang, H. N., Lee, M., Loh, T. J., Choi, S.-W., Oh, H. K., Moon, H., Cho, S., Hong, S.-E., Kim, D. H., Sheng, Z., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.11.006 · Cited by 34
Storbeck, M., Hupperich, K., Gaspar, J. A., Meganathan, K., Carrera, L. M., Wirth, R., Sachinidis, A., & Wirth, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089020 · Cited by 34
Becerra, S., Montes, M., Hernández-Munaín, C., & Suñé, C. (2015) · RNA · doi:10.1261/rna.047258.114 · Cited by 34
Özden, Ö., Bishehsari, F., Bauer, J. I., Park, S., Jana, A., Baik, R., Sporn, J. C., Staudacher, J. J., Yazıcı, C., Krett, N. L., et al. (2016) · Scientific Reports · doi:10.1038/srep26273 · Cited by 34
Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer
Miwa, T., Nagata, T., 小島, 博., Sekine, S., & Okumura, T. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4063 · Cited by 34
Lai, F., Jiang, C. C., Farrelly, M. L., Zhang, X. D., & Hersey, P. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328353eff2 · Cited by 33
Shiraishi, T., Eysturskarð, J., & Nielsen, P. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-342 · Cited by 32
QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2
Lu, W., Feng, F., Xu, J., Lu, X., Wang, S., Wang, L., Lu, H., Wei, M., Yang, G., Wang, L., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29502 · Cited by 32
Hirschfeld, M., Ouyang, Y. Q., Jaeger, M., Erbes, T., Orlowska‐Volk, M., Hausen, A. Z., & Stickeler, E. (2015) · BMC Cancer · doi:10.1186/s12885-015-1088-1 · Cited by 32
Liu, X., Gómez-Pinillos, A., Loder, C., Pau, E. C. D. S., Qiao, R., Unger, P. D., Kurek, R., Oddoux, C., Melamed, J., Gallagher, R. E., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.008 · Cited by 30
Oudin, M. J., Hughes, S. K., Rohani, N., Moufarrej, M. N., Jones, J. G., Condeelis, J. S., Lauffenburger, D. A., & Gertler, F. B. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9775-5 · Cited by 30
Li, F., Fang, Z., Zhang, J., Li, C., Liu, H., Xia, J., Zhu, H., Guo, C., Qin, Z., Li, F., et al. (2016) · Cell Research · doi:10.1038/cr.2016.111 · Cited by 30
Balsamo, M., Mondal, C., Carmona, G., McClain, L. M., Riquelme, D. N., Tadros, J., Ma, D., Vasile, E., Condeelis, J. S., Lauffenburger, D. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35298 · Cited by 30
Choi, E. S., Kim, H., Kim, H., Choi, Y., & Goh, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05247-7 · Cited by 30
Lin, J., Lee, J. H. J., Paramasivam, K., Pathak, E., Wang, Z., Pramono, Z. A. D., Lim, B., Wee, K. B., & Surana, U. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.001 · Cited by 30
Faria, M., Matos, P., Pereira, T., Cabrera, R., Cardoso, B. A., Bugalho, M. J., & Silva, A. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172689 · Cited by 29
Hase, M. E., Yalamanchili, P., & Visa, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604235200 · Cited by 28
Palve, V. C., & Teni, T. R. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-135 · Cited by 28
Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways
Li, G., Li, Y., Wang, H., Wei, S., Chen, J., Chen, Y.-H., Xu, W., Jie, Q., Zhou, Q., Li, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7602 · Cited by 28
Wiesmann, N., Strozynski, J., Beck, C., Zimmermann, N., Mendler, S., Gieringer, R., Schmidtmann, I. M., & Brieger, J. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx006 · Cited by 28
MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
Kim, J., & Bae, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079626 · Cited by 27
DeMicco, A., Naradikian, M. S., Sindhava, V. J., Yoon, J., Gorospe, M., Wertheim, G. B. W., Cancro, M. P., & Bassing, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500512 · Cited by 27
Tilio, M., Gambini, V., Wang, J., Garulli, C., Kalogris, C., Andreani, C., Bartolacci, C., Elexpuru-Zabaleta, M., Pietrella, L., Hysi, A., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.028 · Cited by 26
Zheng, X. Y., Zhan, Z., Naren, D., Li, J., Yan, T., & Gong, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185053 · Cited by 26
Kajita, K., Kuwano, Y., Kitamura, N., Satake, Y., Nishida, K., Kurokawa, K., Akaike, Y., Honda, M., Masuda, K., & Rokutan, K. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-012-0745-2 · Cited by 24
Regulation of fibronectin alternative splicing by a basement membrane‐like extracellular matrix
Srebrow, A., Blaustein, M., & Kornblihtt, A. R. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02382-7 · Cited by 24
Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer
Qu, X., Liu, J., Zhong, X., Li, X., & Zhang, Q. (2015) · Oncology Letters · doi:10.3892/ol.2015.3457 · Cited by 24
Wei, M., Zhu, L., Li, Y., Chen, W., Han, B., Wang, Z., He, J., Yao, H., Yang, Z., Zhang, Q., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01969.x · Cited by 22
Cited by
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Self-citationVitting-Seerup, K., & Sandelin, A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz247 · Cited by 338
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Metadata
- Authors
- Urbanski, L. M., Leclair, N., & Anczuków, O.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2018-04-25
- Volume
- 9
- Issue
- 4
- Pages
- e1476-e1476
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W2800987064
- Cited by
- 389
- References
- 420
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.